Compounds > tebipenem
Page last updated: 2024-11-11

tebipenem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tebipenem: an oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9800194
CHEMBL ID576981
SCHEMBL ID14769588
MeSH IDM0484285

Synonyms (25)

Synonym
tebipenem
CHEMBL576981
ljc-11036
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, (4r,5s,6s)-
(1r,5s,6s)-6-(1(r)-hydroxyethyl)-1-methyl-2-(1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl)-1-carba-2-penem-3-carboxylic acid
q2twq1i31u ,
unii-q2twq1i31u
161715-21-5
tebipenem [who-dd]
tebipenem [mi]
CS-3444
SCHEMBL14769588
AC-35391
HY-A0076
DTXSID40167227
C21522
AKOS030526611
(4r,5s,6s)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
AS-75271
(4r,5s,6s)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4r-[4a,5b,6b(r*)]]-
ljc 11036
Q27286930
(4r,5s,6s)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
A899347

Research Excerpts

Overview

Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections.

ExcerptReferenceRelevance
"Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections. "( Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber
Ambrose, PG; Bhavnani, SM; Conde, H; Cotroneo, N; Friedrich, LV; Jones, S; VanScoy, BD, 2023)		2.68

Actions

ExcerptReferenceRelevance
"Tebipenem displays a broad spectrum of activity against anaerobic, gram-positive, and gram-negative pathogens, including extended-spectrum β-lactamase producing Enterobacterales."( Tebipenem pivoxil hydrobromide-No PICC, no problem!
Cho, JC; Clark, M; Kronsberg, KA; Sodhi, V, 2021)		2.79

Toxicity

ExcerptReferenceRelevance
"The incidence of adverse reactions related to symptoms and signs was 28."( [Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections].
Baba, S; Furukawa, M; Furuya, N; Suzuki, K; Totsuka, K; Ubukata, K; Yamanaka, N, 2009)		0.61

Pharmacokinetics

ExcerptReferenceRelevance
" We therefore performed an population pharmacokinetic analysis using plasma TBPM concentrations obtained from pediatric patients with otolaryngological infection or bacterial pneumonia (0."( Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia.
Hayashi, H; Kijima, K; Koresawa, T; Kurosawa, T; Mitomi, N; Morita, J; Sato, N; Shibasaki, S; Suzuki, H; Totsuka, K, 2008)		0.63
" Cmax of TBPM in the non-fasting state was lowered to approximately 60% of that in the fasting state, however AUC(0-infinity) and urinary excretion of TBPM in the non-fasting state were almost equivalent to those in the fasting state when TBPM-PI fine granules were administered."( [Effect of diet on the pharmacokinetics of tebipenem pivoxil fine granules in healthy male volunteers].
Aizawa, K; Morita, J; Nakashima, M; Takata, T, 2009)		0.62
" The primary pharmacokinetic parameters such as ka, kel, Vd/F and Tlag were estimated by the Bayesian method and then the secondary pharmacokinetic parameters such as tmax, Cmax, t1/2 and AUC were calculated."( [Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections].
Hayashi, H; Kijima, K; Koresawa, T; Kurosawa, T; Morita, J; Sato, N; Shibasaki, S; Totsuka, K, 2009)		0.64

Compound-Compound Interactions

ExcerptReferenceRelevance
"We evaluated the antituberculosis (anti-TB) activity of five β-lactams alone or in combination with β-lactamase inhibitors against 41 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains."( In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.
Doi, N; Horita, Y; Kazumi, Y; Maeda, S, 2014)		0.4

Bioavailability

Tebipenem is being developed as the first oral carbapenem for treatment of complicated urinary tract infections (cUTIs) in adults. Tebipenm pivoxil hydrobromide is a novel orally bioavailable prodrug that binds to penicillin-binding proteins.

ExcerptReferenceRelevance
" Tebipenem is the active form of tebipenem pivoxil, a novel oral carbapenem antibiotic that has a high level of bioavailability in humans, in addition to the above-mentioned features."( Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae.
Baba, N; Gomi, S; Ohsawa, F; Takeuchi, Y; Watanabe, T; Yamada, M, 2008)		1.53
" In conclusion, the absorption rate of TBPM-PI was reduced in the non-fasting state after the administration of TBPM-PI fine granules, but intake of food had little influence on the absorption amount of TBPM."( [Effect of diet on the pharmacokinetics of tebipenem pivoxil fine granules in healthy male volunteers].
Aizawa, K; Morita, J; Nakashima, M; Takata, T, 2009)		0.62
" (1) In mouse, rat, dog and monkey, TBPM-PI were absorbed quickly, and the bioavailability was (71."( [Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals].
Aoki, M; Hayashi, H; Kato, K; Kijima, K; Kurosawa, T; Morita, J; Shibasaki, S; Suzuki, K, 2009)		0.67
" This agent is a prodrug to improve intestinal absorption of TBPM, an active form, and an absorption rate of TBPM-PI is higher than those of other prodrug-type β-lactam antibiotics."( Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport.
Iguchi, M; Kato, K; Kikuchi, A; Kuraoka, E; Kurosawa, T; Shibasaki, S; Shirasaka, Y; Suzuki, H; Tamai, I, 2010)		0.64
" SPR994 is a novel formulation of the orally bioavailable pivoxil prodrug of SPR859 (tebipenem) and is being developed as the first oral carbapenem for treatment of complicated urinary tract infections (cUTIs) in adults."( Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.
Jain, A; Pucci, MJ; Rubio, A, 2018)		0.7
"Tebipenem pivoxil hydrobromide is a novel orally bioavailable prodrug of tebipenem, a carbapenem antimicrobial, that binds to penicillin-binding proteins, inhibiting the synthesis of the bacterial cell wall."( Tebipenem pivoxil hydrobromide-No PICC, no problem!
Cho, JC; Clark, M; Kronsberg, KA; Sodhi, V, 2021)		3.51
" Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales, including extended-spectrum beta-lactamase-producing and fluoroquinolone-resistant strains."( Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Critchley, IA; Dane, A; Eckburg, PB; Jain, A; Keutzer, T; Kwak, H; Melnick, D; Moore, G; Muir, L; Phelan, AM; Talley, AK; Walpole, S, 2022)		2.15
"Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem prodrug of the active agent tebipenem with broad-spectrum activity against drug-resistant Enterobacterales."( Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding.
Asempa, TE; Fouad, A; Nicolau, DP; Quintiliani, R, 2022)		2.44
"Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections."( Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber
Ambrose, PG; Bhavnani, SM; Conde, H; Cotroneo, N; Friedrich, LV; Jones, S; VanScoy, BD, 2023)		2.68

Dosage Studied

Tebipenem pivoxil hydrobromide is expected to have the potential to decrease the seizure threshold. It will likely require renal dosage adjustment for patients with altered renal function due to high renal clearance.

ExcerptRelevanceReference
" In order to treat these infections effectively, it is important to design optimal dosing regimens based on the pharmacokinetics/pharmacodynamics (PK/PD) relationships, which can be characterized by clarifying the pharmacokinetics of tebipenem (TBPM) in the pediatric population."( Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia.
Hayashi, H; Kijima, K; Koresawa, T; Kurosawa, T; Mitomi, N; Morita, J; Sato, N; Shibasaki, S; Suzuki, H; Totsuka, K, 2008)		0.81
" The majority of dosage was excreted out of body by 48 hours after administration."( [Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals].
Aoki, M; Hayashi, H; Kato, K; Kijima, K; Kurosawa, T; Morita, J; Shibasaki, S; Suzuki, K, 2009)		0.67
" Design and synthesis, in vitro and in vivo evaluation of diversified prodrugs of ertapenem, one of the only once daily dosed carbapenems is described."( Design, synthesis, and evaluation of prodrugs of ertapenem.
Bradley, P; Cama, L; Hafey, MJ; Ji, C; Meinke, PT; Nicoll-Griffith, DA; Olsen, DB; Rindgen, D; Singh, SB; Soll, R; Sun, W; Suzuki, T; Wang, L; Wang, N; Wu, H; Yu, H; Zhang, B, 2013)		0.39
" As with other carbapenems, tebipenem pivoxil hydrobromide is expected to have the potential to decrease the seizure threshold and will likely require renal dosage adjustment for patients with altered renal function due to high renal clearance."( Tebipenem pivoxil hydrobromide-No PICC, no problem!
Cho, JC; Clark, M; Kronsberg, KA; Sodhi, V, 2021)		2.36
" Using the 90% CI criteria, Cmaxand AUC0-8 values for tebipenem were found to be bioequivalent following alternative methods of administration compared with oral dosing of the whole tablet."( Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding.
Asempa, TE; Fouad, A; Nicolau, DP; Quintiliani, R, 2022)		1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1311365Antibacterial activity against Enterococcus faecalis ATCC 19433 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID521325Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06663 isolate harboring Met377Ile, Ser385Thr and Asn526Lys mutations in penicillin-binding protein 3 by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID567480Bactericidal activity against gBLNAR Haemophilus influenzae JPH002 assessed as reduction in bacterial load at MIC after 6 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567473Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567470Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567481Bactericidal activity against gBLNAR Haemophilus influenzae JPH1306 assessed as reduction in bacterial load at MIC after 4 hrs by time-kill analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567471Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID521323Antimicrobial activity against rifampin-resistant Haemophilus influenzae Rd clone by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID567472Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID1871991Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis2022European journal of medicinal chemistry, Feb-05, Volume: 229Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID567476Bactericidal activity against gBLNAR Haemophilus influenzae JPH002 assessed as reduction in bacterial load at MIC after 4 hrs by time-kill analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567485Bactericidal activity against gBLNAR Haemophilus influenzae JPH1306 assessed as reduction in bacterial load at MIC after 6 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567475Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567479Bactericidal activity against gBLNAR Haemophilus influenzae JPH002 assessed as reduction in bacterial load at MIC after 4 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID521324Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06647 isolate harboring Asn526Lys mutation in penicillin-binding protein 3 by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID1311377Antibacterial activity against Mycobacterium tuberculosis2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID1311364Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID567474Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID567477Bactericidal activity against gBLNAR Haemophilus influenzae JPH002 assessed as reduction in bacterial load at MIC after 6 hrs by time-kill analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID772174Apparent permeability of the compound in pig LLC-PK1 cells2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Design, synthesis, and evaluation of prodrugs of ertapenem.
AID567483Bactericidal activity against gBLNAR Haemophilus influenzae JPH1306 assessed as reduction in bacterial load at MIC after 2 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567484Bactericidal activity against gBLNAR Haemophilus influenzae JPH1306 assessed as reduction in bacterial load at MIC after 4 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567482Bactericidal activity against gBLNAR Haemophilus influenzae JPH1306 assessed as reduction in bacterial load at MIC after 6 hrs by time-kill analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID567478Bactericidal activity against gBLNAR Haemophilus influenzae JPH002 assessed as reduction in bacterial load at MIC after 2 hrs by time-kill analysis in presence of 10% human serum2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.41)18.2507
2000's15 (21.13)29.6817
2010's36 (50.70)24.3611
2020's19 (26.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.25 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index5.96 (4.65)
Search Engine Demand Index68.99 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (47.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (11.11%)5.53%
Reviews6 (8.33%)6.00%
Case Studies1 (1.39%)4.05%
Observational0 (0.00%)0.25%
Other57 (79.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
arotinolol
arotinolol: structure given in first source; arotinolol is the (+-)-isomer		3.5110aromatic amide;
thiophenes
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		3.5110aromatic ether;
nitrile;
polyether;
tertiary amino compound
cefuroxime
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.		2.4110carbamate ester;
cephalosporin
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		7.1110branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.0510N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		3.5110phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
tosufloxacin
tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.		3.9301,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.0510penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		2.0510organic heterobicyclic compound;
organonitrogen heterocyclic compound
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		2.0510azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.2110monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		7.9840beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		3.3260penicillin allergen;
penicillin		antibacterial drug
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		3.5110[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.5110benzamides;
carboxylic ester
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		2.0510alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.0510cephalosporinantibacterial drug;
drug allergen
cefprozil
[no description available]		2.4520cephalosporin;
semisynthetic derivative		antibacterial drug
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		3.360cephalosporinfungal metabolite
fropenem
[no description available]		2.9940faropenem
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.9940carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
sanfetrinem
sanfetrinem: orally absorbed hexetil ester of GV-104326		2.0510
panipenem
panipenem: synthetic cpd; structure given in first source		2.7530organic molecular entity
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		3.1310carbapenems
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.0510macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		4.2550beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
amdinocillin pivoxil
Amdinocillin Pivoxil: Pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin.. pivmecillinam : A penicillanic acid ester that is the [(2,2-dimethylpropanoyl)oxy]methyl ester and prodrug of mecillinam.		2.0610penicillanic acid ester;
penicillin;
pivaloyloxymethyl ester		antibacterial drug;
antiinfective agent;
prodrug
garenoxacin
garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.		2.0510aromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
non-steroidal anti-inflammatory drug
carbapenems
[no description available]		17.41658
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		4.89100beta-lactam antibiotic allergen;
beta-lactam
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.42209-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		11.6451carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		3.5110aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		4.5770alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
linezolid
[no description available]		2.1310acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.2110cyclodextrin
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.0510macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
pa 824
pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source		3.5110
u 100480
U 100480: structure given in first source		3.5110
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.5110
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		2.0510carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
bedaquiline
bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.		3.5110aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
cefuroxime
[no description available]		2.45203-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		2.05101,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		2.46201,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
cefpodoxime
[no description available]		2.4520carboxylic acid;
cephalosporin		antibacterial drug
cilastatin
[no description available]		2.0510carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
s 1006
S 1006: structure given in first source. cefcapene : A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibacterial.		2.45201,3-thiazoles;
carbamate ester;
carboxylic acid;
cephalosporin;
enamide;
secondary carboxamide		antibacterial drug
nitrocefin
nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source		2.0510
cefditoren pivoxil
[no description available]		2.97401,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester		antibacterial drug;
prodrug
opc-67683
OPC-67683: an antitubercular agent		3.5110piperidines
cefdinir
[no description available]		2.7430cephalosporin;
ketoxime		antibacterial drug
avibactam
avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		3.4750azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas		antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefditoren
cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.		8.1750carboxylic acid;
cephalosporin		antibacterial drug
rwj 54428
RWJ 54428: structure in first source		2.0510
l 084
L 084: an oral carbapenem with a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio group at the C-2 position; structure in first source		3.2250carbapenems;
pivaloyloxymethyl ester
cp 70429
sulopenem: a penem antibiotic		2.920
cefdinir
Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.. cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.		2.4220
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		2.1510benzoxazole
cilastatin, imipenem drug combination
Cilastatin, Imipenem Drug Combination: Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.		2.0510
btz 043
[no description available]		3.5110
mk-7655
relebactam: structure in first source		2.610
lymecycline
Lymecycline: A semisynthetic antibiotic related to TETRACYCLINE. It is more readily absorbed than TETRACYCLINE and can be used in lower doses.. lymecycline : A tetracycline-based broad-spectrum antibiotic. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall.		3.5110
pbtz169
macozinone: an antitubercular agent; structure in first source		3.5110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.1310cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ceftobiprole
ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).		2.0510cephalosporin;
thiadiazoles		antimicrobial agent
amg531
[no description available]		3.5110
ConditionIndicatedRelationship StrengthStudiesTrials
Extensively Drug-Resistant Tuberculosis
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.		03.3310
Enteric Fever
[description not available]		02.3110
Typhoid Fever
An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.		02.3110
Infectious Diseases
[description not available]		04.12100
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		04.12100
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		04.9921
Necrotizing Pyelonephritis
[description not available]		05.221
Pyelonephritis
Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.		05.221
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		010.9171
Disease, Pulmonary
[description not available]		02.4110
Lung Diseases
Pathological processes involving any part of the LUNG.		02.4110
E coli Infections
[description not available]		02.6120
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.6120
Diabetic Feet
[description not available]		04.0290
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		04.0290
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		04.0290
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6920
Atypical Mycobacterial Infection, Disseminated
[description not available]		02.6620
Electrocardiogram QT Prolonged
[description not available]		03.711
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		03.711
Bacterial Infections, Gram-Negative
[description not available]		03.0910
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		03.0910
Community Acquired Infection
[description not available]		02.8130
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		03.9640
Pneumonia
Infection of the lung often accompanied by inflammation.		03.9640
Bacterial Disease
[description not available]		06.0252
Bacterial Infections
Infections by bacteria, general or unspecified.		06.0252
Haemophilus Infections
Infections with bacteria of the genus HAEMOPHILUS.		03.0140
Middle Ear Inflammation
[description not available]		0340
Acute Disease
Disease having a short and relatively severe course.		02.2110
Otitis Media
Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.		0340
Infections, Respiratory
[description not available]		02.110
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.110
Tuberculosis, Drug-Resistant
[description not available]		02.110
Pulmonary Consumption
[description not available]		02.110
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		02.110
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.110
Absence Seizure
[description not available]		02.4820
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		07.4820
Blood Poisoning
[description not available]		02.1310
Infections, Klebsiella
[description not available]		02.1310
Infections, Pseudomonas
[description not available]		02.1310
Infections, Staphylococcal
[description not available]		02.1310
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		02.1310
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.1310
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.1310
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.1310
Sinus Infections
[description not available]		02.1310
Sinusitis
Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.		07.1310
ENT Diseases
[description not available]		05.0433
Pneumonia, Pneumococcal
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.		03.4311
Hepatic Veno Occlusive Disease
[description not available]		02.0510
Hepatic Veno-Occlusive Disease
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.		02.0510
Bacterial Pneumonia
[description not available]		02.4620
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		02.4620
Group A Strep Infection
[description not available]		02.0610
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		02.0610
Infections, Pneumococcal
[description not available]		02.7530
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.		02.7530
Middle Ear Effusion
[description not available]		07.0810
Otitis Media with Effusion
Inflammation of the middle ear with a clear pale yellow-colored transudate.		02.0810